ArticleFrontiers in oncology2025

Case Report: Trastuzumab deruxtecan in human epidermal growth factor receptor 2-mutated lung cancer with continuous renal replacement therapy.

Sumin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.